SCDT: Detecting somatic CNVs of low chimeric ratio in cf-DNA

Zhaoyang Qian^{1,2,3,†}, Xiaofeng Wang^{1,2,3,†}, Chang Shi^{1,2,3}, Rui Han⁴, Yaoshen Wang⁴,
Hongmei Zhu^{1,2,3,*}

1. BGI-Shenzhen, Shenzhen 518083, China

2. China National GeneBank, BGI-Shenzhen, Shenzhen 518120, China

3. Binhai Genomics Institute, BGI-Tianjin, BGI-Shenzhen, Tianjin 300308, China

4. BGI Genomics, BGI-Shenzhen, Shenzhen 518083, China

*To whom correspondence should be addressed

†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.

Abstract

Motivation: Sequencing of cell-free DNA (cf-DNA) has enabled Noninvasive Prenatal Testing (NIPT) and “liquid biopsy” of cancers. However, while the aneuploidy and point mutations were focused on by most of NITP and liquid biopsy studies, detecting sub-chromosome CNVs that affect a few to dozens of megabases was rarely reported, likely attributable to the difficulty in accurately identifying them, especially for those present in a small fraction of cf-DNA .

Results: We developed a somatic CNV detection tool (SCDT), for detecting sub-chromosome CNVs in cf-DNA using whole genome sequencing (WGS) data or off-target reads in target sequencing data. Additional to using control samples for correcting genome position specific bias, two GC correction steps were performed,

which regressed GC content of DNA fragments and that of genome bins, respectively.

After GC correction, the coefficients of variation of copy ratios approximated the lower boundary of theoretical values, suggesting removing of almost all systematic errors. Finally, CNVs were detected by a piecewise least squares fitting based segmentation algorithm, which outperformed other segmentation methods. We applied SCDT on simulated and real maternal plasma samples, and target cf-DNA sequencing of 118 normal individuals and 240 cancer patients, and demonstrated high sensitivity and specificity.

Availability: SCDT is available at https://github.com/Martiantian/Somatic_cnv_detect_tool.

Contact: zhuhongmei@genomics.cn

Supplementary Information: Supplementary data are available at Bioinformatics online

1 Introduction

Copy number variation (CNV) is one type of structural variation with duplication or deletion event that affects a considerable number of base pairs (Sharp, *et al.*, 2005), altering gene dosage and subsequently affecting functional and biological behavior of cells. CNVs have been known to greatly contribute to a wide repertoire of human diseases, including genetic disease, developmental and neuropsychiatric disorders (Kirov, *et al.*, 2009; Sebat, *et al.*, 2007; Walsh, *et al.*, 2008) and almost all types of cancers (Pollack, *et al.*, 2002; Shlien and Malkin, 2009; Taylor, *et al.*, 2008).

Detecting CNVs in human genomes has been a routine clinical test for disease screening, diagnosis and therapy guiding.

In the recent years, plasma cell free DNA (cf-DNA) sequencing has been broadly applied to non-invasive genetic diagnostics. One of the most important applications of cf-DNA sequencing is non-invasive prenatal testing (NIPT), which directly sequences cf-DNA extracted from maternal blood to identify likely aneuploidy of the fetus. However, NIPT generally focused on whole-chromosome aneuploidies (triploid 13/18/21, X, XXY and XYY) which account for only 30% of all live births with a chromosome abnormality. Recent progression has been made in genome-wide screening of sub-chromosomal CNVs with significantly smaller sizes, which have a considerably higher incidence (0.5-1.7%) than whole-chromosome aneuploidy in human pregnancy (Brady, *et al.*, 2016) , and could be associated with genetic disease including DiGeorge syndrome (22q11.2 deletion), Cri-du-chat syndrome (5p deletion), Angelman syndrome (15q11–q13 deletion) and 1p36 deletion syndrome. However, non-invasively detecting CNVs with small chimeric fraction without previously known positions is much more challenging than aneuploidy testing. After two proof-of-concept studies (Jensen, *et al.*, 2012; Peters, *et al.*, 2011) on a few cases, several subsequent studies focused on achieving statistical significance using relatively high depth whole genome sequencing (more than 100 million reads). These methods were based on statistical test on individual genomic bins, or required several consecutive bins to be significant (Srinivasan, *et al.*, 2013; Yu, *et al.*, 2013) However, in addition to the cost of relatively deep whole genome sequencing, high rates of false

positives (FPs) and false negatives (FNs) in these individual-bin test methods would restrict their application in real clinical use. Some other methods reduced the requirement on sequencing depth by employing sliding window strategy (Straver, *et al.*, 2014) or using binary segmentation with dynamic threshold (Chen, *et al.*, 2013), and aimed at detecting large fragment aberrations (>10M) using low-coverage sequencing data. Lo et al, reported 60.7% (17/28) of accuracy for analyzing 3Mb to 42Mb de novo CNVs using 4-10 M reads, while the sensitivity increased to 92.9% using relative higher sequencing depth up to 120M reads (Lo, *et al.*, 2016). Yin et al developed a method to identify 69 of 73 (94.5%) CNVs identified by array CGH using 10 million reads, with a specificity of 98.1% (Yin, *et al.*, 2015). A method based on unified Hidden Markov model was developed for detecting fetal CNVs and achieved great resolution (400 kb) with fetal fraction of 13%, however, is only feasible using deep sequencing data and information of parental SNP genotypes, which is unavailable in routine NIPT (Rampasek, *et al.*, 2014).

Another inspiring application of cf-DNA sequencing is to be used as a surrogate for tissue biopsy, named“liquid biopsy”, for screening and monitoring tumor-derived genomic aberrations. Circulating tumor DNA (ct-DNA) can be detected in the plasma of cancer patients, and has great potential in clinical management of cancers. A plenty of targeted therapies have been developed to target copy number change of some cancer driver genes, e.g. high level amplifications of ERBB2, MET, CCND1 and FGFR1 (Baselga and Swain, 2009; Christensen, *et al.*, 2005; Musgrove, *et al.*, 2011; Turner, *et al.*, 2010) , etc. However, current reported noninvasive assays seldom

include detection of actionable CNVs, which may be due to the serious difficulty on accurately identifying CNVs in ct-DNA, as ct-DNA typically accounts for a little proportion (<10%) of cf-DNA, even in many advanced stage cancer patients(Adalsteinsson, *et al.*, 2017). Most published studies employed reads counting strategy for genome bins and simple statistics such as Z-test to identify CNVs. Chan et al used individual bin based Z-test on 4 high depth whole genome sequencing (WGS) (17X) of HCC cases (Chan, *et al.*, 2013). Heitzer et al calculated segment z-score after CNV segmentation using circular binary segmentation (CBS) algorithm in 13 plasma samples of 9 metastatic prostate patients, which usually have high tumor DNA concentrations (Heitzer, *et al.*, 2013). Xu et al performed individual bin z-score based CNV analysis on 31 patients, and showed that recognizable CNVs were only detectable in most samples with large tumor size (tumor dimension > 50 mm) (Xu, *et al.*, 2015). However, method accurately determining the CNV fragment using shallow depth WGS data with low FPs is scarce and tools for identifying tumor-derived CNV in cf-DNA of a wide range of patients would have significant clinical values.

In this study, we present a novel approach named Somatic CNV Detecting Tool (SCDT), which has ability to use shallow WGS data and target sequencing data to detect genome-wide microdeletions or microduplications (MDs) without a priori knowledge of an event's location. To maximize the ability to remove “noise” introduced by library construction, PCR process and sequencing, and intrinsic difference between genome regions, we used control samples to correct genome position specific bias, and two GC correction steps to regress GC content of DNA

fragments and that of genome bins, respectively. Following that we nearly achieve the theoretical minimum of random fluctuation in copy ratios. A segmentation algorithm based on piecewise least squares fitting and a rigorous statistical method is applied to finally determine the CNVs. We show that SCDT recovered all “spiking in” MDs with ≥ 3 Mbp length and $\geq 5\%$ chimeric fraction ($\geq 10\%$ mix ratio) using about 25 million sequencing reads ($0.3 \times$ genome coverage). Finally, we applied our algorithm in three cf-DNA datasets of abnormal maternal plasma samples, normal samples and a large cohort of patients with various types of cancer, respectively, and demonstrated the feasibility of SCDT for precisely detecting clinically relevant CNVs in cf-DNA.

2 Methods

2.1 Data preparation and Overview of methods

We use bam format files as input of SCDT, including at least one sample as control. The control samples should be prepared using the same protocol with the test samples, including methods for library constructing and sequencing. Duplicate reads should be removed in the bam files using software such as Picard-tools and Samtools. The aligned genome positions of reads were extracted from the bam files, with a filtering step to discard reads with low mapping quality or high number of mismatches. Additionally, for using target sequencing data as input, reads located adjacent to (< 500 bp) the target region were discarded from the bam files.

Firstly, the whole genome should be divided into non-overlapping bins (defined as level-1 bins) with fixed length assigned by users. Read depth count (RDC) of each

level-1 bin is obtained by counting reads with start positions in it. However, each DNA fragment was not counted by 1, but instead by 1 divided by a correction factor corresponding to its CG content (section 2.2). Secondly, the RDCs of each test and control sample were centralized to 1 by dividing their medians, and then we used the mean of centralized RDCs at each bin across the control samples to generate a reference data, which is used to normalize the centralized RDCs of test samples to obtain the copy ratios (section 2.3). Thirdly, we merged a fixed number (defined by users) of level-1bins into the level-2 bin. The copy ratio of each level-2 bin was calculated as the mean of copy ratios of level-1 bins inside it. Subsequently, we performed a second step of GC correction based on regression for the copy ratios and GC content of level-2 bins using general liner model (GLM) (section 2.4). Finally, we performed CNV segmentation by a piecewise least squares fitting on the copy ratios of level-2 bins (section 2.5), and tested the significance of each CNV segment under the assumption of independent and identical distribution of copy ratios (section 2.6) (Supplementary Fig S1).

2.2 First step of GC correction based on single DNA fragment

Firstly, we divided the GC-content range (0-1) into 1000 intervals (0.001 per interval), followed by calculating GC-content distribution on the 1000 GC intervals for 170 base-pair (bp) sliding windows (sliding with 1bp each time) in the reference genome (except the sex chromosomes). Secondly, for single-end sequencing data, we extended the sequencing reads to 170bp based on its alignment position in the reference

genome. Then we calculated GC-content distribution of extended reads on the 1000 GC intervals for each sample. GC-content intervals higher than 70% and lower than 20% were discarded for their intense fluctuation of read counts. For each DNA fragment, a correction factor cf was assigned by:

$$cf_{gc^i} = n_{gc^i} / n_{gc^i}^0$$

where gc^i is GC interval of the DNA fragment i , $n_{gc^i}^0$ is distribution density of gc^i in the reference genome, n_{gc^i} is distribution density of gc^i in sequenced DNA fragments of this sample (Fig 1A). So we can get the normalized read depth count (NRDC) of each level-1 bin by

$$nrdc_j = \sum_{i \in bin_j} 1 / cf_{gc^i}$$

in which i represents the ID of reads whose start position located in the j th bin.

2.3 Control RDC construction and copy ratio calculation

To reduce systematic bias caused by factors other than GC-content, we used the copy ratio of test sample NRDC to the control reference NRDC (CNRDC) for further analysis. CNRDC is calculated by the following procedures: Firstly, to eliminate the influence of variation in sequencing data volumes, all the samples including test samples and control samples should be performed with centralization of NRDC by dividing the median NRDC of all genome bins. Secondly, to reduce the random fluctuation in the CNRDC and thus reduce the fluctuation in the final copy ratio, we construct CNRDC by averaging the NRDCs at each bin across the control samples.

After obtaining the CNRDC, we can get the corrected copy ratio (CCR) for the test

samples by

$$ccr_j = \frac{nrcd_j}{cnrdc_j}$$

in which ccr_j is the corrected copy ratio of the j th bin, $nrcd_j$ is the NRDC of the j th bin in the test sample, and $cnrdc_j$ is the CNRDC of the j th bin. Additionally, to avoid the frequent germline CNVs, outlying bins with $CNRDC < m_{CNRDC} * 0.7$ or $CNRDC > m_{CNRDC} * 1.4$ were removed, in which m_{CNRDC} is the median value of CNRDC of all autosomal bins.

For detecting CNVs at various level of length, we performed CNV segmentation on detection bins (defined as level-2 bins), whose length (should be an integer multiple of level-1 bin length) are assigned by users. The copy ratio of each level-2 bin was obtained by averaging CCR of all level-1 bins within it.

2.4 Second step of GC-correction

Even with the first step of GC correction described in 2.2, we observed that the CCRs were still generally correlated with GC-content (Supplementary Fig S2). The remaining bias, though slightly increasing the variance of CCR, may produce false positives in several GC abnormal regions in the genome, e.g. chr1p and chr19. Thus a second step of GC-correction was performed to further remove the remaining GC bias, by a generalized linear regression for CCR and GC-content of level-2 bins, which can be illustrated as:

$$\begin{aligned} ccr_j &= a * gc_j^2 + b * gc_j + c + e \\ ccr'_j &= e_j \end{aligned}$$

in which a, b and c are coefficients of regression, gc_j is GC-content of j th level-2 bin, ccr'_j is the GC-corrected copy ratio of j th level-2 bin, and e_j is the residual of ccr_j . Then, ccr'_j was used instead of ccr_j as input for CNV segmentation algorithm.

2.5 CNV Segmentation

To locate the breakpoints of CNVs and determine the CNV status of segments, we employed a piecewise least squares estimation model based on stepwise regression for each chromosome, which could also be described as piecewise linear fitting of ladder type and identified the breakpoints of ladders one by one. We minimized sum of squares of residuals to get the least squares estimation, as described below.

If we have obtained the sorted breakpoint set $E = \{(0,1), (j_2, j_2+1), (j_3, j_3+1), \dots, (j_k, j_k+1), (n, n+1)\}$ ($1 < j_2 < j_3 < \dots < j_k < n$, each breakpoint is indicated by two consecutive genomic bins and n is the total bin numbers of this chromosome) after fitting k ladders to a chromosome, we can obtain the estimation of ccr_j for each bin:

$$\hat{ccr}_j = \begin{cases} \overline{ccr}_{1,j_2} & j = 1, \dots, j_2 \\ \vdots & \vdots \\ \overline{ccr}_{j_{k-1}+1, j_k} & j = j_{k-1}+1, \dots, j_k \\ \overline{ccr}_{j_k+1, n} & j = j_k+1, \dots, n \end{cases}$$

in which $\overline{ccr}_{j_{k-1}+1, j_k} = 1/(j_k - j_{k-1}) \sum_{j=j_{k-1}+1}^{j_k} ccr_j$, or the mean value of ccr_j from

$(j_{k-1}+1)$ th bin to j_k th bin. So the sum of squares of residuals is

$$ESS_k = \sum_{j=1}^n (ccr_j - \overline{ccr}_j)^2$$

Next, we introduce the detailed steps of the piecewise linear fitting model by taking the chromosome i for example. For the j th bin of chromosome i , let $D_i = \{z_j^i \mid z_j^i = \widehat{ccr}_j^i - \widehat{ccr}_j^i + 1, j = 1, 2, \dots, n_i\}$ be the discriminant set for chromosome i , in which n_i is the total bin number.

Step 0: Get the initial value of coefficient of variation (CV). We firstly calculated CV of each 20 consecutive level-2 bins in all autosomes by

$$CV = S_{CCR} / \overline{CCR}$$

where S_{CCR} and $\overline{CCR}$ are the standard variation and the average of CCRs, respectively. Then the initial CV (cv_0) could be estimated by averaging the smallest 30% CVs of all 20 consecutive level-2 bins in the whole genome, and subsequently be used in the loop termination conditions for the piecewise linear fitting. When $k=1$, the breakpoint set is $E_k^i = \{(0,1), (n_i, n_i + 1)\}$, which has only two breakpoints and one CNV segment. The estimation of $\widehat{ccr}_j^i$ could be calculated by the mean of all ccr_j^i in chromosome i .

Step 1: Judge whether to terminate the loop of piecewise linear fitting for chromosome i . For discriminant set D_i , we can calculate the CV value of ladder k (cv_k) by

$$cv_k = s_i / \bar{z}_i,$$

in which $\bar{z}_i = 1/n_i \sum_{j=1}^{n_i} z_j^i$ is the mean value of D_i set, $s_i = \sqrt{1/n_i \sum_{j=1}^{n_i} (z_j^i - \bar{z}_i)^2}$ is

the standard variation of D_i set. When $k=1$, if $cv_k - \gamma * cv_0 \leq 0$ (γ is a coefficient assigned by users, and $\gamma = 1$ by default) we terminate the loop for piecewise linear fitting. And when $k > 1$, if

$$(cv_{k-1}^2 - cv_k^2)(n-1) < (r/2)^2 * L/B$$

$$\text{or } cv_k - \gamma * cv_0 \leq 0$$

we terminate the loop, where r is a coefficient assigned by users corresponding to the lowest chimeric fraction for CNV detecting (3% by default), B is the length of level-2 bin (1M bp by default) and L is the smallest size for CNV detecting ($3 \times b$, by default). Otherwise, $k=k+1$, and then go to step 2.

.

Step 2: Add one optimal point to breakpoint set E_{k-1}^i by traverse the potential new breakpoint set R_{k-1}^i . After adding one more breakpoint $j \in R_{k-1}^i$ to E_{k-1}^i , we can get the new breakpoint set $E_{k,j}^i$ and the new sum of squares of residuals $ESS_{k,j}^i$. To get the optimal breakpoints for fitting the chromosome, we minimize the $ESS_{k,j}^i$ over all $j \in R_{k-1}^i$:

$$j = \arg \min_{j \in R_{k-1}^i} ESS_{k,j}^i$$

$$\text{and } ESS_k^i = ESS_{k,j}^i$$

Step 3: Test whether the new breakpoint set is significant for fitting chromosome i . According to the stepwise regression model, if $k > 2$, we should test whether including each one of the previous breakpoints in E_{k-1}^i is more significant for fitting chromosome i than including the new breakpoint in step 2. If including a previous breakpoint is not more significant than including the new breakpoint, this previous breakpoint should be removed from the breakpoint set while $k=k-1$, until all the remained breakpoints are more significant than the new breakpoint. Then, go to step 1. The significance of including a breakpoint is assessed by calculating the decrease in

ESS.

2.6 Significance test

For chromosome i of the test sample, we assume that $\hat{ccr}_j^i = ccr_j^i + \varepsilon_j^i (j=1, \dots, n_i)$ and ε_j^i follow independent identical normal distribution $N(0, \sigma_i^2)$. The unbiased estimation of $\hat{\sigma}_i$ can be calculated by

$$\hat{\sigma}_i = \sqrt{\frac{1}{n_i - 1} \sum_{j=1}^{n_i} (\varepsilon_j^i - \bar{\varepsilon}_i)^2}, \bar{\varepsilon}_i = \frac{1}{n_i} \sum_{j=1}^{n_i} \varepsilon_j^i.$$

So the CCR in a normal bin should follow distribution of $N(1, \hat{\sigma}_i^2)$. Therefore, we can infer that average CCR of the k th segment ($\overline{CCR}_k$) follows distribution of $N(1, \frac{\hat{\sigma}_i^2}{j_{k+1} - j_k})$ under the H_0 hypothesis of $\overline{CCR}_k = 1$, and the significance of the k th segment to reject H_0 could be tested.

Because the additional deviation in the copy ratios induced by real CNVs could not be determined before going through the pipeline, the first run of step 2.5 and 2.6 was only used to define normal regions in the whole genome, and thus used to set parameters cv_0 for the second run of these two steps to obtain the final segmentation results and the significance of each CNV. Before the second run of step 2.5 and 2.6, the copy ratios across the genome should be centralized again using the average copy ratio of normal bins defined by the first run. The initial coefficient of variation cv_0 used in the step 0 of 2.5 in the second run is also reset by cv of normal bins at the first run.

3 Results

3.1 Theoretical limitation of CNV detectability in cf-DNA

The sequenced DNA fragments only took a very small part of the cf-DNA in the circulation, so the process of blood drawing, cf-DNA extracting and library construction could be regarded as random sampling of cf-DNA from an infinite population. Thus the read count examined in a certain genome bin should follow Poisson distribution. To calculate theoretical limitation of CNV detectability in cf-DNA, we firstly assessed the theoretical random fluctuation of copy ratios. The RDC in the i th bin could approximate to a random variable following Poisson distribution $P(\lambda_i)$ with a mathematical expectation of λ_i . However, λ_i may be different for different i because some inherent characteristics in different genomic regions could affect the read count, such as the mappability (Ha, *et al.*, 2012). We have:

$$\lambda_i = P_i * N / b$$

in which N is the total effective reads of this sample, b is the total number of level-2 bins in the whole genome, and P_i is a position specific coefficient to adjust the reads count in i th bin.

Considering X and Y are independent, the random fluctuation of copy ratios could be evaluated by

$$\begin{aligned} \text{Var}\left(\frac{X/\lambda_1}{Y/\lambda_2}\right) &= \text{Var}(X/\lambda_1)\text{Var}(\lambda_2/Y) + \text{Var}(X/\lambda_1)E^2(\lambda_2/Y) + \text{Var}(\lambda_2/Y)E^2(X/\lambda_1) \\ &> \text{Var}(X/\lambda_1)E^2(\lambda_2/Y) \end{aligned}$$

in which λ_1 is mathematical expectation for test sample X and λ_2 is mathematical

expectation for the control reference Y.

It is easy to deduce a lower bound of CV

$$CV_{\left(\frac{X/\lambda_1}{Y/\lambda_2}\right)} > \frac{\sqrt{\text{Var}(X/\lambda_1)E^2(\lambda_2/Y)}}{E(X/\lambda_1)E(\lambda_2/Y)} = \sqrt{\text{Var}(X/\lambda_1)} = \sqrt{\frac{1}{\lambda_1}}$$

For brevity, we assume that $P_i = 1$ for all i in each sample, and use the variance of all bins in a sample as the variance of each bin. Then we can get:

$$\lambda_i = N/b$$

$$CV_{\left(\frac{X/\lambda_1}{Y/\lambda_2}\right)} > \sqrt{b/N}$$

In order to evaluate the effectiveness of our GC-correction method, we applied this method to 67 normal maternal plasma samples, and compared the actual coefficient of variation (ACV) before and after GC-correction with theoretical lower limit of coefficient of variation (TCV) for the copy ratios (CR). Before GC-correction, we identified various degrees of correlation between CR and GC-content in the 67 samples, implying that different samples were affected by different levels of GC bias, even with identical number of PCR cycles in the library process. We also identified a broad range of correlation between CRs of different samples (Fig 1B), suggesting the non-independence of CR in different samples. After GC-correction, ACVs were greatly reduced, as well as the linear correlation between GC-content and CRs, and the correlation of CRs between different samples. Moreover, we approximately achieved the theoretical lower limit of TCV after GC-correction (Fig 1C). These results implied that systematic bias in CRs are mostly contributed by GC bias, which

could be almost completely removed using our GC-correction method. After GC-correction, CR of different samples obeyed the assumption of independence in step 2.6. However, factors other than GC-bias that introduce systematic bias in the RDC should also affect RDC of the control samples, and thus should be normalized in the CR.

We next assessed theoretical limit of detecting power given a confidence coefficient (p -value). A significant CNV segmentation could be modeled as several continuous bins with deviant CRs. Approximately, we assumed that CR of single bin followed an i.i.d normal distribution, thus the detecting power could be assessed by

$$r/2 \geq z_{1-\alpha/2} \cdot ACV / \sqrt{L/B} \geq z_{1-\alpha/2} \cdot TCV / \sqrt{L/B}$$

where $r/2$ is the chimeric fraction of a heterozygous CNV, α is the confidence level, $z_{1-\alpha/2}$ is the $1-\alpha/2$ quantile of standard normal distribution, L is the length of CNV, and B is the level-2 bin size. Supplementary Figure S3 shows the smallest chimeric fraction of detectable CNV with various lengths and amount of effective reads. Given $N=25M$, $b=3000$, $B=1M$, $L=3M$, and $p=10e-5$, we could infer that $r/2 = 2.80\%$.

3.2 Simulation Study and Comparison between segmentation methods

To evaluate the performance of SCDT, we blended cf-DNA from a healthy female with DNA from tissues of aborted fetuses whose CNVs had been determined by G-banding karyotyping, to simulate cf-DNA from maternal plasma with abnormal fetus. Using this method and tissues of 11 aborted fetuses, we obtained 108 simulated

samples with various mixture ratios (MR), including 3%, 5%, 8%, 10%, 15% and 20%. All the simulated samples were sequenced with 35bp single-end reads on BGISEQ 500 platform. After filtering out reads with low mapping quality ($<Q30$) or high mismatch numbers, the average amount of effective reads for each sample is averagely 25M (8M- 69M), which is applicable in current NITP test. Considering that the CNVs of aborted fetuses are different from each other, in this experiment we used the median NRDC of all the samples as the control reference for normalization.

We set the level-1 bin size to 100kb and the level-2 bin size to 1M, and then used SCDT to analyze these samples. To reduce false positives, we required a CNV segment with p -value smaller than $10e-5$, and with copy ratio >1.01 or <0.99 . Here, we defined a predicted CNV as a true positive if it overlapped with at least 50% of a spike-in CNV. Using SCDT we detected all the spike-in CNVs with chimeric fraction $\geq 5\%$ (mixture ratios $\geq 10\%$) and length $\geq 3M$ and had no false positive with length $\geq 3M$ after filtering out putative germline CNVs (Fig 2). We then compared our results with the theoretically detection limitation and found that SCDT detected most of theoretically detectable CNVs, though missed some near the line of theoretically limitation (Supplementary Table S1). However, the spike-in fractions evaluated from CRs of CNVs were lower than expected (Supplementary Fig S4), probably because of failure to remove some large fragment DNA during preparation of fetal DNA.

We compared the performance of SCDT on the simulated samples with the state-of-the-art CNV detection methods, including BIC-seq (Xi, *et al.*, 2011), DNACopy (Venkatraman and Olshen, 2007), Control-FREEC (Boeva, *et al.*, 2012)

and CNV-seq (Xie and Tammi, 2009). Considering that CBS and BIC-seq didn't have GC correction workflow, these methods were evaluated following preprocessing by our GC-correction method. For each detector, we adjusted the parameters and cutoffs until the results achieved the fewest false positives with sensitivity of 60% (Supplementary Method). We observed that our GC-normalization step greatly improved performance of CBS and BIC-seq. For the 56 samples with theoretically detectable CNVs of size $\geq 3\text{M}$, the segmentation method of SCDT had the highest sensitivity (89.29%), followed by CBS (82.14%) and BIC-seq (76.80%). When considering all the samples with the CNV size more than 3M, the segmentation method of SCDT also had higher sensitivity (59.77%) than CBS (52.87%) and BIC-seq (49.43%), while the false discovery rates for SCDT, CBS and BIC-seq were around 1.89%, 8% and 0%. We then compared the average sum of length of false positives in each sample at different level of sensitivity, and demonstrated that the segmentation method of SCDT outperformed the other methods (Fig 3).

3.3 Real Data Analysis

3.3.1 Abnormal maternal plasma samples

To further evaluate the performance of SCDT, we applied it to cf-DNA sequencing data of real clinical samples, including maternal plasma and plasma of cancer patients. 34 maternal plasma samples carrying abnormal fetal CNVs previously determined by amniotic fluid puncture and G-banding karyotyping were sequenced with average effective reads of 18M (11M - 31M). We chose another 9 normal maternal plasma samples to construct the control reference. The parameter setting was the same with

the simulated data described above. We detected all confirmed CNVs in the 34 cases with only one false positive with length $\geq 3\text{M}$, indicating high sensitivity and specificity of SCDT (Fig 4; Supplementary Table S2). We applied SCDT on another 7 cases of maternal plasma reported with abnormal genotyping by BGI NIPT workflow, but reported negative by amniocentesis and G-banding karyotyping. Interestingly, we observed chimeric CNVs in all these 7 cases, with great significance (Supplementary Fig S5). None of these women had been identified with a cancer, and inconsistency in these cases might result from chimeric placenta, abnormal hematologic clones of maternal, or false negative reports of amniocentesis.

3.3.2 Target sequencing of cf-DNA for normal individuals

We then investigated CNVs in 118 cf-DNA target capture sequencing data from normal individuals. All these samples were target enriched using a panel covering 1.7 megabases before sequenced with paired-end 100bp reads on Hiseq2500 platform. To detect CNVs using off-target reads as analogue of low-depth WGS data, we filtered out reads on or near target regions to build whole genome sequencing depth for these plasma samples. The number of off-target reads is 58M averagely (27-88M). Using $p < 10e-5$ for cut-off and filtering out a few frequent false positive regions (totally 27M) that are affected by polymorphic CNVs or harbor long centromere and telomere sequence, the false positive callings was evaluated to be 0.03% of the whole genome (Supplementary Fig S6). However, the false discovery rate should be overestimated, for some of false positives were induced by germline events.

3.3.3 Target sequencing of cf-DNA for cancer patients

Finally, the same method for analyzing target-off reads was applied on additional 240 cf-DNA samples of patients with various types of cancers (Supplementary Table S3), which were captured by the same target panel used for normal individuals, with off-target reads of 45M averagely (16-170M). 10 female samples in the normal dataset were used to build the control reference. Blood cell DNA of these patients was also target sequenced as control to determine somatic point mutations. The most frequent copy number changes in 240 samples included gains of chr1q, 3q, 8q and loss of chr1p, 4, 8p, 17p, consisting with the CNV profiles in cancers (Fig 5, Supplementary Table S4). We evaluated the concentration of ct-DNA in cf-DNA using both point mutations and CNVs, and identified a high correlation between them ($r=0.72$, Supplementary Method). Samples detected with CNVs have significantly more point mutations and higher mutational variant allele frequency (VAF, $p<1e-10$) (Fig 5). Of the 107 samples that have >10% of the genome detected with CNVs, 97 (90.7%) were with average mutational VAF >2%, while in other 86 cancer samples that have $\leq 1\%$ of the genome detected with CNVs, only 6 (7.0%) were with average mutational VAF >2% and another 54 (62.8%) sample were absence of point mutations. In addition, we used VAF of point mutations to assess the copy number of CNVs, and detected several targetable agents including high amplification ($CN \geq 7$) of EGFR ($n=9$), MET ($n=3$), ERBB2 ($n=5$), KRAS ($n=5$) FGFR1 ($n=1$), CCND1 ($n=7$), CDK4 ($N=4$) et al (Fig 6; Supplementary Fig S7). However, high amplification ($CN \geq 7$) of some other genes known to have a role in drug resistance could also be detected in several samples, such as MYC ($n=8$) and MCL1($n=4$), etc.

Discussion

Deviation in the copy ratio of each genome bin is composed of at least two components, one is natural fluctuation caused by the random sampling process in blood drawing, DNA extracting, library constructing and sequencing, and the other is systematic fluctuation caused by factors such as GC non-uniform distribution or different success rate of sequencing or reads mapping in certain genome regions. According to the theoretical statistic rules, the natural fluctuation would result in poisson distribution of the final read count per genomic region, and thus can be exactly evaluated. We showed that the limit detection ability for a CNV with certain chimeric fraction and length only depends on the read count per bin, according to the theoretical statistic rules. In this study we introduced a GC correction approach to remove almost all the deviation in copy ratios contributed by non-random factors in cf-DNA sequencing data. However, as FP rate particularly concern clinical application in large scale population screening, and even a low FP rate could produce considerable FP cases, avoiding FPs of biological sources, including germline CNVs, placental mosaicism and maternal abnormality, are noteworthy in addition to reducing FPs of technical source. Several studies have identified CNVs of hemopoietic origin in blood cell-DNA in about 1-3% of normal individuals (Jacobs, *et al.*, 2012; Laurie, *et al.*, 2012), while they are reasonable to also present in cf-DNA, which is mainly derived from blood cell DNA (Sun, *et al.*, 2015).

Cf-DNA sequencing brought immense opportunities for molecular diagnosis in

clinical settings, especially in the field of cancer. However, while point mutations and methylation of cf-DNA have been widely used as biomarkers for cancer screening, early detection, treatment guiding, and disease monitoring, the cf-DNA copy-number signatures, another important kind of genomic aberrations and targets of a handful of drugs, is still seldom mentioned and evaluated in studies, partially because of the low ct-DNA fraction and technique difficulty in overcoming the low signal to noise ratio for CNV detection. Another concern is that quantifying low chimerical CNVs using WGS data requires big data size and increases the cost. However, we demonstrated that using target-off reads, the by-product of target sequencing, was a feasible way to profile somatic CNVs in cf-DNA. In addition to providing information in guiding therapeutic decisions, interrogating cf-DNA CNVs may also help to evaluate the therapy efficiency and monitor tumor recurrence. However, according to our analysis, the detection limit of chimeric ratio of CNV is inversely proportional to the square of read count, which indicates that 10 folds improvement of sensitivity requires 100 folds of sequencing data, and thus hampers the interrogating of ultra-low chimeric CNVs. Therefore point mutations may be better biomarkers for samples with low ct-DNA fraction. Moreover, as ct-DNA fraction in early stage cancers is extremely low (0.1% or less), CNVs in ct-DNA are hard to be profiled and thus not economically applicable to early cancer detection. Overall, integrating CNV analysis into liquid biopsy offers a global view of genomic aberrations, and provides more opportunity for clinical management of cancer.

To accurately find more common chromosomal abnormalities with smaller size at

earlier gestational stage and cancer stage is an important goal of non-invasive clinical testing. As continuous reduction in sequencing cost, larger data size will become available soon with affordable cost. This allows for more precise diagnostics as our method is expected to perform better with increased sequencing depth. A higher coverage will allow for more stable calls and using smaller bin sizes while keeping the read depth per bin high enough to detect changes confidently.

Acknowledgements and Funding

The research reported in this work was supported by BGI Academy of Life Sciences and BGI Institute of big data without any official funding.

References

- Adalsteinsson, V.A., *et al.* (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors, *NAT COMMUN*, **8**, 1324.
- Baselga, J. and Swain, S.M. (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3, *NAT REV CANCER*, **9**, 463-475.
- Boeva, V., *et al.* (2012) Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data, *BIOINFORMATICS*, **28**, 423-425.
- Brady, P., *et al.* (2016) Clinical implementation of NIPT - technical and biological challenges, *CLIN GENET*, **89**, 523-530.
- Chan, K.C., *et al.* (2013) Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing, *CLIN CHEM*, **59**, 211-224.
- Chen, S., *et al.* (2013) A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing, *Prenat Diagn*, **33**, 584-590.
- Christensen, J.G., *et al.* (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention, *CANCER LETT*, **225**, 1-26.
- Ha, G., *et al.* (2012) Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer, *GENOME RES*, **22**, 1995-2007.
- Heitzer, E., *et al.* (2013) Tumor-associated copy number changes in the circulation of

patients with prostate cancer identified through whole-genome sequencing, *GENOME MED*, **5**, 30.

Jacobs, K.B., *et al.* (2012) Detectable clonal mosaicism and its relationship to aging and cancer, *NAT GENET*, **44**, 651-658.

Jensen, T.J., *et al.* (2012) Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma, *CLIN CHEM*, **58**, 1148-1151.

Kirov, G., *et al.* (2009) Support for the involvement of large copy number variants in the pathogenesis of schizophrenia, *HUM MOL GENET*, **18**, 1497-1503.

Laurie, C.C., *et al.* (2012) Detectable clonal mosaicism from birth to old age and its relationship to cancer, *NAT GENET*, **44**, 642-650.

Lo, K.K., *et al.* (2016) Limited Clinical Utility of Non-invasive Prenatal Testing for Subchromosomal Abnormalities, *AM J HUM GENET*, **98**, 34-44.

Musgrove, E.A., *et al.* (2011) Cyclin D as a therapeutic target in cancer, *NAT REV CANCER*, **11**, 558-572.

Peters, D., *et al.* (2011) Noninvasive prenatal diagnosis of a fetal microdeletion syndrome, *N Engl J Med*, **365**, 1847-1848.

Pollack, J.R., *et al.* (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors, *Proc Natl Acad Sci U S A*, **99**, 12963-12968.

Rampasek, L., *et al.* (2014) Probabilistic method for detecting copy number variation in a fetal genome using maternal plasma sequencing, *BIOINFORMATICS*, **30**, i212-i218.

Sebat, J., *et al.* (2007) Strong association of de novo copy number mutations with autism, *SCIENCE*, **316**, 445-449.

Sharp, A.J., *et al.* (2005) Segmental Duplications and Copy-Number Variation in the Human Genome, *The American Journal of Human Genetics*, **77**, 78-88.

Shlien, A. and Malkin, D. (2009) Copy number variations and cancer, *GENOME MED*, **1**, 62.

Srinivasan, A., *et al.* (2013) Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma, *AM J HUM GENET*, **92**, 167-176.

Straver, R., *et al.* (2014) WISECONDOR: detection of fetal aberrations from shallow sequencing maternal plasma based on a within-sample comparison scheme, *NUCLEIC ACIDS RES*, **42**, e31.

Sun, K., *et al.* (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments, *Proc Natl Acad Sci U S A*, **112**, E5503-E5512.

Taylor, B.S., *et al.* (2008) Functional copy-number alterations in cancer, *PLOS ONE*, **3**, e3179.

Turner, N., *et al.* (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer, *CANCER RES*, **70**, 2085-2094.

Venkatraman, E.S. and Olshen, A.B. (2007) A faster circular binary segmentation algorithm for the analysis of array CGH data, *BIOINFORMATICS*, **23**, 657-663.

Walsh, T., *et al.* (2008) Rare structural variants disrupt multiple genes in

neurodevelopmental pathways in schizophrenia, *SCIENCE*, **320**, 539-543.

Xi, R., *et al.* (2011) Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion, *Proc Natl Acad Sci U S A*, **108**, E1128-E1136.

Xie, C. and Tammi, M.T. (2009) CNV-seq, a new method to detect copy number variation using high-throughput sequencing, *BMC BIOINFORMATICS*, **10**, 80.

Xu, H., *et al.* (2015) Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular Carcinoma by Next Generation DNA Sequencing, *J CANCER*, **6**, 247-253.

Yin, A.H., *et al.* (2015) Noninvasive detection of fetal subchromosomal abnormalities by semiconductor sequencing of maternal plasma DNA, *Proc Natl Acad Sci U S A*, **112**, 14670-14675.

Yu, S.C., *et al.* (2013) Noninvasive prenatal molecular karyotyping from maternal plasma, *PLOS ONE*, **8**, e60968.

|

Figures:

Figure 1. GC correction in 67 normal maternal plasma samples. (A) GC correction factors for DNA fragments based on the GC content by equation (2). This figure only shows ten samples randomly selected from the 67 normal maternal plasma samples. (B) Comparison of Pearson's correlation between copy ratios of different samples before and after GC correction. This figure demonstrates that GC correction significantly ($p < 2.2 \times 10^{-16}$; Wilcoxon signed rank test with continuity correction using the absolute values of the Pearson's correlation value) reduced the Pearson's correlation between copy ratios of different samples. (C) The theoretical coefficient of variations (TCVs) and the actual coefficient of variations (ACVs) of copy ratios before and after GC correction. The ACVs after GC correction are much closer to the lower bounds of TCVs than the ACVs without GC correction. ACVs after GC correction are only 0.0015(0.00028-0.0057) larger than the lower bounds of TCVs, implying that our GC correction approximately removed all the systematic errors in the copy ratios, including that caused by GC-biases.

Figure 2. Performance of SCDS on the data of simulated maternal plasma samples. The top panel presents the lengths of spike-in amplifications (red bars) and deletions (blue bars). The lower panel presents the detecting results of spike-in CNVs, while whites blocks denote that these simulations had not been performed.

Figure 3. Performance of different methods on the simulated maternal plasma samples. Performances of SCDS and the state-of-the-art CNV detection methods, including BIC-seq (Xi, *et al.*, 2011), DNAcopy (Venkatraman and Olshen, 2007), Control-FREEC (Boeva, *et al.*, 2012) and CNV-seq (Xie and Tammi, 2009), were evaluated by the average length of all false positives in samples with certain sensitivities on the simulated maternal plasma samples (62 samples with CNV length $\geq 3\text{M}$ and spike-in fraction ≥ 0.05). Parameter setting of different methods was detailed in the results section.

Figure 4. CNVs detected in the real clinical maternal plasma DNA samples carrying abnormal fetal DNA. Each sample is presented by an annular area between two adjacent circular lines. Amplifications and deletions are highlighted by red and blue, respectively.

Figure 5. Mutations and CNVs detected in the cf-DNA of 240 cancer patients. (A) Fraction of CNV regions in the whole genome of each sample are showed by red bars. (B) Average variant allele frequencies (VAFs) of detected mutations in each sample are showed by blue bars. (C) Mutation spectrum of 240 cf-DNA samples. (D) CNV spectrum of 240 cf-DNA samples, ordered by genome positions from chromosome1 (top) to chromosome22 (bottom). Gains and losses were detected with the cutoff of $p < 10e-5$, and highlighted by red and blue, respectively.

Figure 6. Examples of clinical relevant CNVs in cf-DNA of cancer patients. Gains and losses are highlighted by red and blue, respectively. The average VAF of mutations in four samples (from top to bottom) were 3.40%(n=11), 3.78%(n=24), 3.45%(n=5), 4.05%(n=4), respectively.

Supplementary Methods

Parameters for BIC-seq, DNACopy, Control-FREEC and CNV-seq

For BIC-seq, the initial bin size was set to 1M and the penalty parameter was chosen as 1.5. We chose the candidate CNVs as regions with P-values less than 0.01 and $\log R > 0.05$ or < -0.05 . Default parameters were used for DNACopy. For Control-FREEC, the parameter setting include window = 1000000, degree = 4, breakPointThreshold = 2.0 and forceGCcontentNormalization = 1. For CNV-seq, 0.75M was chosen as the windows size and the parameter of global-normalization was used. The other parameters include minimum-windows-required = 6 and log2-threshold changing from 0.01 to 0.1 for obtaining different levels of sensitivity.

Estimation of ct-DNA fraction in cf-DNA

Considering that homozygous deletion of long DNA fragment ($>10M$) was not likely to occurred in cancer genomes, so we estimate the ct-DNA fraction using the lowest copy ratio of long DNA fragment deletions ($>10M$) with $p < 10e-5$. Assuming that μ is the lowest copy ratio of long DNA fragment deletions, we estimate the ct-DNA fraction to be $(1 - \mu) \times 2$. If no long DNA fragment deletions is detected with $p < 10e-5$, the ct-DNA fraction was estimated to be 0.

Test dataset

The sequence data (fastq) have been deposited in the NCBI SRA database with the accession number of SRA525461.

Supplementary Figures:

Figure S1. Workflow of SCDT.

Figure S2. Comparison of CVs of copy ratios between two-step GC correction and one-step GC correction. CV of copy ratios after two-step GC correction (horizontal-axis) and only the first step GC correction (vertical-axis in the left panels) or only the second step GC correction (vertical-axis in the right panels) on the low-depth whole genome sequencing (WGS) data of 67 normal maternal plasma samples(A) or on the 138 target sequencing of normal samples(B).

Figure S3. The theoretical CNV detection power determined by reads numbers, CNV length and the chimeric fraction of CNVs. The default confidence level is 0.001 and the size of test bin was set to 1M. Lines of different colors indicate the minimal detectable chimeric proportion with certain reads number and CNV length. The right vertical axis indicates the minimal detectable chimeric proportion of target CNV with 20 million reads.

Figure S4. Evaluated chimeric fractions of the simulated spike-in CNVs.

Figure S5. CNV profiles of 7 real maternal plasma samples which were identified to be normal by amniocentesis. Copy number gains and losses were highlighted by red and blue, respectively.

Figure S6. CNV spectrum in 138 target sequencing of normal cf-DNA samples, ordered by genome positions from chromosome1 (left) to chromosome22 (right). Gains and losses were detected with the cutoff of $p < 10e-5$, and highlighted by red and blue, respectively.

Supplementary Tables

Supplementary table 1

Sample	Chr	Start	End	Length	Estimate_copy_ratio	P_value	Type	Validated	Spike-in Fraction	Theoretical_P_value
CL100005923_L01_17	1	2.00E+06	8999999	7.00E+06	0.898607539	7.88E-108	Del	YES	0.2	1.63E-136
CL100005923_L01_17	1	1.00E+06	2.00E+06	1.00E+06	0.921543529	2.24E-10	Del	YES	0.2	1.63E-136
CL100005923_L01_18	1	1.00E+06	8999999	8.00E+06	0.922911807	3.34E-45	Del	YES	0.15	1.56E-48
CL100005923_L01_19	1	1.00E+06	8999999	8.00E+06	0.94540306	2.21E-20	Del	YES	0.1	5.84E-19
CL100005923_L02_1	8	0	6999999	7.00E+06	1.096399256	0	Dup	YES	0.2	0
CL100005923_L02_1	4	0	9.00E+06	9.00E+06	0.901840503	1.75E-121	Del	YES	0.2	2.20E-142
CL100005923_L02_12	5	0	11999999	1.20E+07	0.946974904	2.17E-27	Del	YES	0.2	7.19E-113
CL100005923_L02_13	5	0	11999999	1.20E+07	0.965571992	4.51E-12	Del	YES	0.15	6.31E-74
CL100005923_L02_15	5	0	9999999	1.00E+07	0.972481006	3.66E-07	Del	YES	0.05	1.70E-06
CL100005923_L02_17	22	1.90E+07	20999999	2.00E+06	0.938785193	2.02E-09	Del	YES	0.2	1.31E-30
CL100005923_L02_2	8	0	6999999	7.00E+06	1.071508954	0	Dup	YES	0.15	0
CL100005923_L02_2	4	0	8999999	9.00E+06	0.924526802	1.56E-63	Del	YES	0.15	2.22E-70
CL100005923_L02_3	8	0	6999999	7.00E+06	1.04682088	0	Dup	YES	0.1	0
CL100005923_L02_3	4	0	10999999	1.10E+07	0.955535745	1.10E-25	Del	YES	0.1	2.15E-34
CL100005923_L02_4	4	2.00E+06	8999999	7.00E+06	0.969164158	2.17E-08	Del	YES	0.05	1.03E-06
CL100005923_L02_4	8	0	4999999	5.00E+06	1.027246911	6.37E-05	Dup	YES	0.05	4.03E-05
CL100005923_L02_6	15	2.30E+07	28999999	6.00E+06	0.897981514	9.36E-87	Del	YES	0.2	2.82E-70
CL100005923_L02_7	15	2.30E+07	28999999	6.00E+06	0.923807773	8.18E-66	Del	YES	0.15	8.15E-54
CL100005923_L02_9	15	2.30E+07	28999999	6.00E+06	0.952274325	3.91E-19	Del	YES	0.1	3.32E-18
CL100006330_L01_1	4	0	5999999	6.00E+06	0.914280779	5.95E-75	Del	YES	0.2	2.35E-100
CL100006330_L01_12	7	7.30E+07	73999999	1.00E+06	0.937111848	4.23E-06	Del	YES	0.15	2.57E-12
CL100006330_L01_17	5	0	9999999	1.00E+06	0.945340937	0.0001113	Del	YES	0.05	9.44E-06
CL100006330_L01_2	4	0	4999999	5.00E+06	0.94288694	3.97E-22	Del	YES	0.15	6.13E-46
CL100006330_L01_20	4	0	5999999	6.00E+06	0.922463126	2.15E-48	Del	YES	0.2	1.36E-80
CL100006330_L01_3	4	0	5999999	6.00E+06	0.956993805	1.67E-12	Del	YES	0.1	8.17E-17
CL100006330_L01_6	5	1.00E+06	23999999	2.30E+07	0.912873622	2.10E-197	Del	YES	0.2	2.35E-279
CL100006330_L01_6	5	0	1.00E+06	1.00E+06	0.877299161	3.56E-20	Del	YES	0.2	2.35E-279
CL100006330_L01_7	5	0	23999999	2.40E+07	0.932907537	4.29E-125	Del	YES	0.15	2.14E-161
CL100006330_L01_8	5	5.00E+06	23999999	1.90E+07	0.957997386	3.27E-31	Del	YES	0.1	1.40E-59
CL100006330_L02_11	15	2.40E+07	28999999	5.00E+06	0.905775183	2.05E-60	Del	YES	0.2	3.08E-86
CL100006330_L02_11	15	2.30E+07	2.40E+07	1.00E+06	0.94011912	7.41E-06	Del	YES	0.2	3.08E-86
CL100006330_L02_12	15	2.30E+07	28999999	6.00E+06	0.936739358	8.15E-29	Del	YES	0.15	4.57E-44
CL100006330_L02_13	15	2.30E+07	28999999	6.00E+06	0.965064307	8.34E-07	Del	YES	0.1	1.56E-15
CL100006330_L02_16	22	1.90E+07	2.10E+07	2.00E+06	0.910399169	6.53E-27	Del	YES	0.2	1.46E-43
CL100006330_L02_16	22	2.10E+07	21999999	1.00E+06	0.935011032	9.17E-08	Del	YES	0.2	1.46E-43
CL100006330_L02_17	22	1.90E+07	21999999	3.00E+06	0.941845293	7.20E-14	Del	YES	0.15	6.55E-21
CL100006330_L02_18	22	1.70E+07	20999999	4.00E+06	0.964708536	9.38E-06	Del	YES	0.1	2.29E-08
CL100006330_L02_6	15	2.40E+07	28999999	5.00E+06	0.901724201	2.40E-75	Del	YES	0.2	8.53E-83
CL100006330_L02_6	15	2.30E+07	2.40E+07	1.00E+06	0.939121122	1.15E-06	Del	YES	0.2	8.53E-83
CL100006330_L02_7	15	2.30E+07	28999999	6.00E+06	0.929928128	8.52E-46	Del	YES	0.15	2.72E-47
CL100006330_L02_8	15	2.30E+07	27999999	5.00E+06	0.963597874	1.44E-08	Del	YES	0.1	2.48E-18
CL100014014_L01_11	17	1.70E+07	1.80E+07	1.00E+06	0.880599301	2.50E-24	Del	YES	0.2	2.64E-57
CL100014014_L01_11	17	1.90E+07	19999999	1.00E+06	0.919495266	3.62E-11	Del	YES	0.2	2.64E-57
CL100014014_L01_13	17	1.70E+07	19999999	3.00E+06	0.911354222	2.48E-21	Del	YES	0.15	3.45E-26
CL100014014_L01_16	15	2.50E+07	28999999	4.00E+06	0.917197011	7.35E-46	Del	YES	0.2	7.46E-97
CL100014014_L01_16	15	2.30E+07	2.50E+07	2.00E+06	0.932232947	9.43E-16	Del	YES	0.2	7.46E-97
CL100014014_L01_17	15	2.30E+07	2.90E+07	6.00E+06	0.950646161	9.11E-19	Del	YES	0.15	2.60E-45
CL100014014_L01_6	15	2.40E+07	28999999	5.00E+06	0.909972719	4.52E-56	Del	YES	0.2	3.24E-73
CL100014014_L01_6	15	2.30E+07	2.40E+07	1.00E+06	0.941341581	9.43E-06	Del	YES	0.2	3.24E-73
CL100014014_L01_7	15	2.40E+07	28999999	5.00E+06	0.945451827	3.43E-16	Del	YES	0.15	1.32E-33
CL100014014_L01_8	15	2.30E+07	3.00E+07	7.00E+06	0.972777748	2.85E-05	Del	YES	0.08	3.68E-10
CL100016513_L01_1	9	1.29E+08	1.40E+08	1.10E+07	1.08079154	0	Dup	YES	0.2	0
CL100016513_L01_1	9	1.40E+08	140999999	1.00E+06	1.101131118	0	Dup	YES	0.2	0
CL100016513_L01_1	1	2.00E+06	3999999	2.00E+06	0.891927582	1.31E-41	Del	YES	0.2	2.59E-69
CL100016513_L01_1	1	1.00E+06	2.00E+06	1.00E+06	0.920281493	6.58E-12	Del	YES	0.2	2.59E-69
CL100016513_L01_10	15	2.30E+07	28999999	6.00E+06	0.897245554	1.76E-30	Del	YES	0.15	2.93E-16
CL100016513_L01_11	15	2.50E+07	27999999	3.00E+06	0.945095742	1.08E-12	Del	YES	0.1	1.76E-19
CL100016513_L01_11	15	2.30E+07	2.40E+07	1.00E+06	0.917003889	2.17E-11	Del	YES	0.1	1.76E-19
CL100016513_L01_12	15	2.30E+07	27999999	5.00E+06	0.967740085	6.13E-05	Del	YES	0.08	4.85E-09
CL100016513_L01_17	15	2.40E+07	28999999	5.00E+06	0.902541467	4.46E-71	Del	YES	0.2	3.01E-80
CL100016513_L01_18	15	2.40E+07	28999999	5.00E+06	0.933047035	9.02E-32	Del	YES	0.15	1.73E-43
CL100016513_L01_19	15	2.30E+07	28999999	6.00E+06	0.956741294	2.61E-12	Del	YES	0.1	2.33E-15
CL100016513_L01_2	9	1.29E+08	140999999	1.20E+07	1.069787048	0	Dup	YES	0.15	0
CL100016513_L01_2	1	2.00E+06	3999999	2.00E+06	0.909694076	1.47E-26	Del	YES	0.15	1.65E-34
CL100016513_L01_2	1	1.00E+06	2.00E+06	1.00E+06	0.941487342	2.97E-06	Del	YES	0.15	1.65E-34
CL100016513_L01_20	15	2.30E+07	28999999	6.00E+06	0.965499419	2.99E-10	Del	YES	0.08	4.09E-13
CL100016513_L01_3	9	1.33E+08	140999999	8.00E+06	1.054394196	0	Dup	YES	0.1	0
CL100016513_L01_3	1	1.00E+06	3999999	3.00E+06	0.946604677	2.78E-14	Del	YES	0.1	4.43E-16
CL100016513_L01_3	9	1.29E+08	1.33E+08	4.00E+06	1.03967374	1.46E-09	Dup	YES	0.1	0
CL100016513_L01_4	9	1.36E+08	140999999	5.00E+06	1.039936108	7.79E-13	Dup	YES	0.08	0
CL100016513_L01_4	9	1.29E+08	1.36E+08	7.00E+06	1.028794894	7.55E-08	Dup	YES	0.08	0
CL100016513_L01_8	15	2.30E+07	28999999	6.00E+06	0.912956061	1.15E-45	Del	YES	0.2	6.09E-63

Supplementary table 2

Sample	Chr	Start	End	Length	Estimate_copy_ratio	P_value	Type	Validated
CL100016513_L02_31	5	0	17999999	1.80E+07	0.887501211	1.39E-137	Del	Yes
CL100016513_L02_33	9	0	38999999	3.90E+07	1.104866778	0	Dup	Yes
CL100016513_L02_37	18	6.10E+07	77999999	1.70E+07	0.900977684	3.62E-106	Del	Yes
CL100016513_L02_38	3	0	34999999	3.50E+07	1.05307488	0	Dup	Yes
CL100016513_L02_42	6	1.03E+08	117999999	1.50E+07	0.938366647	2.52E-34	Del	Yes
CL100017066_L01_12	3	1.82E+08	197999999	1.60E+07	1.134271942	0	Dup	Yes
CL100017066_L01_12	7	1.43E+08	158999999	1.60E+07	0.867450059	6.58E-177	Del	Yes
CL100017066_L01_13	3	0	36999999	3.70E+07	1.042350453	0	Dup	Yes
CL100017066_L01_13	18	0	49999999	5.00E+06	0.947326212	2.38E-08	Del	Yes
CL100017066_L01_14	11	1.10E+08	134999999	2.50E+07	1.04564861	0	Dup	Yes
CL100017066_L01_14	6	1.59E+08	170999999	1.20E+07	0.964109986	4.04E-09	Del	Yes
CL100017066_L01_15	6	1.62E+08	170999999	9.00E+06	0.862799059	2.12E-146	Del	Yes
CL100017066_L01_15	6	1.54E+08	1.62E+08	8.00E+06	0.940716773	2.67E-21	Del	Yes
CL100017066_L01_18	5	1.02E+08	112999999	1.10E+07	1.054948746	0	Dup	Yes
CL100017066_L01_20	2	2.36E+08	242999999	7.00E+06	1.08772313	0	Dup	Yes
CL100017066_L01_20	18	0	99999999	1.00E+07	0.905114039	1.76E-60	Del	Yes
CL100017066_L01_3	12	1.07E+08	133999999	2.70E+07	1.06204632	0	Dup	Yes
CL100017066_L01_3	10	0	29999999	3.00E+06	0.936940142	3.25E-13	Del	Yes
CL100017066_L01_4	9	0	21999999	2.20E+07	1.042862869	0	Dup	Yes
CL100017066_L01_4	12	0	33999999	3.40E+07	1.046307159	0	Dup	Yes
CL100017066_L01_44	21	1.50E+07	23999999	9.00E+06	0.93609728	3.74E-25	Del	Yes
CL100017066_L01_6	4	6.20E+07	85999999	2.40E+07	0.962856732	2.04E-17	Del	Yes
CL100017066_L01_7	3	5.90E+07	97999999	3.90E+07	0.975397351	4.14E-08	Del	Yes
CL100017066_L01_8	1	2.23E+08	248999999	2.60E+07	1.125025541	0	Dup	Yes
CL100017066_L01_8	6	0	49999999	5.00E+06	0.883814707	1.66E-46	Del	Yes
CL100017066_L01_9	3	1.50E+08	197999999	4.80E+07	1.074375309	0	Dup	Yes
CL100017066_L02_21	13	2.00E+07	2.40E+07	4.00E+06	1.070766305	0	Dup	Yes
CL100017066_L02_21	15	7.50E+07	102999999	2.80E+07	1.067374502	0	Dup	Yes
CL100017066_L02_21	13	2.50E+07	26999999	2.00E+06	1.052683185	3.72E-06	Dup	Yes
CL100017066_L02_22	15	9.10E+07	102999999	1.20E+07	1.090749056	0	Dup	Yes
CL100017066_L02_23	13	5.30E+07	7.50E+07	2.20E+07	1.049337076	0	Dup	Yes
CL100017066_L02_23	13	7.50E+07	7.80E+07	3.00E+06	1.101681725	0	Dup	Yes
CL100017066_L02_23	13	7.80E+07	114999999	3.70E+07	0.935872676	2.49E-100	Del	Yes
CL100017066_L02_23	13	4.50E+07	4.90E+07	4.00E+06	1.054928849	3.43E-09	Dup	Yes
CL100017066_L02_24	5	1.70E+07	28999999	1.20E+07	0.918787306	2.39E-34	Del	Yes
CL100017066_L02_25	8	0	22999999	2.30E+07	1.063801078	0	Dup	Yes
CL100017066_L02_26	4	0	39999999	4.00E+07	0.954084728	8.67E-43	Del	Yes
CL100017066_L02_27	8	1.20E+07	47999999	3.60E+07	1.053063259	0	Dup	Yes
CL100017066_L02_27	8	0	7.00E+06	7.00E+06	0.938205434	4.30E-19	Del	Yes
CL100017066_L02_29	10	2.00E+06	1.50E+07	1.30E+07	1.072197238	0	Dup	Yes
CL100017066_L02_29	1	1.00E+06	16999999	1.60E+07	0.920613844	3.95E-81	Del	Yes
CL100017066_L02_32	7	1.22E+08	1.42E+08	2.00E+07	1.055642174	0	Dup	Yes
CL100017066_L02_32	7	1.42E+08	1.48E+08	6.00E+06	0.933183964	7.76E-25	Del	Yes
CL100017066_L02_32	7	1.52E+08	158999999	7.00E+06	0.948429319	3.25E-16	Del	Yes
CL100017066_L02_32	22	4.30E+07	50999999	8.00E+06	1.041045151	5.57E-11	Dup	No
CL100017066_L02_32	7	1.50E+08	1.52E+08	2.00E+06	0.928259239	7.07E-11	Del	Yes
CL100017066_L02_33	1	2.09E+08	248999999	4.00E+07	1.058877287	0	Dup	Yes
CL100017066_L02_34	8	1.13E+08	145999999	3.30E+07	1.039174177	0	Dup	Yes
CL100017066_L02_35	4	0	34999999	3.50E+07	0.946056263	1.77E-55	Del	Yes
CL100017066_L02_36	18	2.00E+07	45999999	2.60E+07	0.954044289	1.72E-28	Del	Yes
CL100017066_L02_37	2	0	30999999	3.10E+07	1.068014316	0	Dup	Yes
CL100017066_L02_37	8	1.20E+08	1.41E+08	2.10E+07	1.050465712	0	Dup	Yes
CL100017066_L02_38	16	3.40E+07	7.80E+07	4.40E+07	1.071450552	0	Dup	Yes
CL100017066_L02_38	16	7.80E+07	89999999	1.20E+07	1.098995091	0	Dup	Yes
CL100017066_L02_45	12	0	33999999	3.40E+07	1.054389375	0	Dup	Yes

Supplementary table 3

Sample	Cancer Type	Number of mutations	Tumor fraction estimated by SNV/indel	Tumor fraction estimated by CNV
14P1008444	Cardia	7	0.209285714	0.351433966
15P6653209-1	Gallbladder	0	0	0
15P6653177-1	Gallbladder	9	0.203888889	0.24462597
14P1011925-1	Gallbladder	17	0.051294118	0.089929658
14P1113003	Unknow	4	0.04025	0.038773001
15P6219946-1	Lung	0	0	0
15P6226246-1	Lung	1	0.012	0
15P6653214-1	Lung	0	0	0
15P6653255-1	Lung	1	0.012	0
15P6658474-1	Lung	2	0.0255	0
14P1006997	Lung	0	0	0
14P1114097-1	Lung	0	0	0
14P1114529-1	Lung	0	0	0
15P0201526-1	Lung	0	0	0
15P0201532-1	Lung	0	0	0
15P6219948-1	Lung	0	0	0
15P6226220-1	Lung	0	0	0
15P6651893-1	Lung	1	0.014	0
15P6652494-1	Lung	0	0	0
15P6653243-1	Lung	0	0	0
15P6615698-1	Lung	0	0	0
15P6651217-1	Lung	6	0.061666667	0.080435927
15P6653199-1	Lung	0	0	0
15P6653269-1	Lung	7	0.040285714	0.052360092
14P1113568	Lung	0	0	0.032423453
15P6658590-1	Lung	0	0	0.025570068
15P6658735-1	Lung	4	0.05975	0.071655274
15P6652529-1	Lung	3	0.035666667	0.065412934
14P1113521	Lung	0	0	0
15P6219928-1	Lung	13	0.059923077	0.070504555
15P6653082-1	Lung	5	0.1208	0.108767513
15P6652808-1	Lung	1	0.006	0
15P6652311-1	Lung	0	0	0
15P0201548-1	Lung	9	0.048666667	0.056340384
15P6653173-1	Lung	7	0.181	0.17344066
14P1112646	Lung	0	0	0
15P6651204-1	Lung	17	0.110705882	0.088645439
14P1114306-1	Lung	3	0.027333333	0.161816718
15P1825167-1	Lung	7	0.059714286	0.073946443
15P6658740-1	Lung	0	0	0.110454377

15P6215168-1	Lung	11	0.093636364	0.096164398
15P0201565-1	Lung	0	0	0
14P1012082	Lung	1	0.01	0
15P6226247-1	Lung	2	0.0175	0.280374985
15P6653260-1	Lung	5	0.206	0.303675861
15P6653227-1	Lung	3	0.068	0.299663748
15P6220091-1	Lung	11	0.137181818	0.081197413
15P0047208-1	Lung	6	0.266333333	0.3484067
15P6653258-1	Lung	3	0.009	0
15P6651928-1	Lung	18	0.226111111	0.266998073
15P6652785-1	Lung	7	0.086142857	0.107690034
15P6652362-1	Lung	1	0.143	0.154604273
15P6650491-1	Lung	13	0.148615385	0.235123776
14P1113520	Lung	23	0.169956522	0.123868105
15P6219987-1	Lung	1	0.01	0
14P1007586-1	Lung	0	0	0
14P1113755-1	Lung	0	0	0
14P1114095-1	Lung	0	0	0
15P6652480-1	Lung	0	0	0
15P6652783	Lung	0	0	0
15P6653171-1	Lung	3	0.007	0
15P6653198-1	Lung	0	0	0
15P6653226-1	Lung	0	0	0
15P6653230-1	Lung	2	0.0665	0.016422112
14P1012513	Lung	10	0.0702	0.078008495
15P6658643-1	Lung	2	0.0085	0
15P6658528-1	Lung	2	0.0105	0
15P6652977-1	Lung	9	0.071	0.307768202
15P6652427-1	Lung	2	0.0165	0
15P6653237-1	Lung	0	0	0
14P1114105-1	Lung	1	0.018	0.02133771
15P6656800-1	Lung	1	0.01	0
15P6658628-1	Lung	3	0.027333333	0.020970937
15P6651917-1	Lung	5	0.0854	0.127497145
14P1112647-1	Lung	0	0	0
14P1113491	Lung	1	0.005	0
14P1007923	Lung	0	0	0
15P6651916-1	Lung	0	0	0
15P6653225-1	Lung	3	0.032666667	0.045263244
15P6651205-1	Lung	1	0.075	0
14P0891664	Lung	6	0.169333333	0
15P6653385-1	Lung	1	0.014	0
15P6652980-1	Lung	2	0.058	0.03019133
15P6653250-1	Lung	7	0.032285714	0.027567631

15P6658739-1	Lung	1	0.027	0.027148833
15P6653239-1	Lung	0	0	0
14P1005328-1	Lung	0	0	0
15P0201529-1	Lung	1	0.005	0
15P0201544-1	Lung	0	0	0
15P6653264-1	Lung	2	0.01	0
14P0973622	Lung	2	0.0115	0
14P1011995	Lung	0	0	0
15P6651144-1	Lung	2	0.025	0.033178599
15P6653235-1	Lung	9	0.047666667	0.033770392
14P1114760-1	Lung	0	0	0
15P6653208-1	Lung	0	0	0
15P6651315-4	Lung	1	0.01	0
15P6653190-1	Lung	12	0.057416667	0.055379965
15P6653196-1	Lung	0	0	0.030212536
15P6653212-1	Lung	2	0.032	0.042098043
15P6658738-1	Lung	1	0.045	0.037710971
15P6220092-1	Lung	8	0.04775	0.049817947
14P1114307-1	Lung	0	0	0
14P1007455	Lung	0	0	0
15P6652773-1	Lung	4	0.0575	0.02997527
14P1113496	Lung	21	0.044619048	0.048638729
15P6653224-1	Lung	1	0.006	0
15P6652486-1	Lung	1	0.032	0.044580806
14P1113495	Lung	1	0.008	0
15P6219936-1	Lung	0	0	0
15P6654813-1	Unknow	1	0.005	0
15P6653144-1	Liver	5	0.0124	0
14P1009599	Liver	0	0	0
15P6653216-1	Liver	8	0.146125	0.196204318
15P6658494-1	Liver	3	0.088666667	0.092800381
14P1114322-1	Liver	4	0.23925	0.372007165
14P1111984	Liver	0	0	0.046137791
15P6653207-1	Liver	0	0	0
15P6653254-1	Liver	0	0	0
15P6653229-1	Liver	3	0.027666667	0.03388115
15P6657920-1	Cervical	1	0.01	0
15P6215252-1	Cervical	2	0.2015	0
15P6652285-1	Cervical	6	0.040166667	0.047674679
14P1114040-1	Cervical	0	0	0
15P6226129-1	Cervical	0	0	0
14P1115157-1	Cervical	10	0.0371	0.048833597
15P6219937-1	Cervical	11	0.034090909	0.061155945
15P6658736-1	Cervical	6	0.015166667	0.019174428

14P1012070	Bone	3	0.011333333	0
14P1112476	Bone	0	0	0
14P1012073	Bone	0	0	0
15P6652525-1	Bone	0	0	0.050822655
15P6651124-1	Melanoma	7	0.038857143	0.05140447
15P6653142-1	Synovial_sarcoma	0	0	0
15P6652777-1	Glioblastoma	0	0	0
14P1113000	Thyroid	0	0	0
14P1113002	Colorectal	0	0	0
14P1114106-1	Colorectal	0	0	0
15P6658485-1	Colorectal	0	0	0.269176289
15P6658716-1	Colorectal	11	0.259	0.174174302
15P6653204-1	Colorectal	5	0.3136	0.201413403
15P6515536R-1	Colorectal	0	0	0
14P1007519	Colorectal	11	0.210727273	0.211610161
15P0201540-1	Colorectal	3	0.047333333	0.371726724
15P6653221-1	Colorectal	1	0.006	0
14P1006572	Colorectal	3	0.043666667	0.051791102
14P0975261	Lymphoma	1	0.009	0
15P6653186-1	Lymphoma	5	0.1298	0.061800504
15P6655982-1	Lymphoma	36	0.191555556	0.27810369
15P6652491-1	Ovarian	0	0	0
15P6650887-1	Ovarian	1	0.068	0
15P6654500-1	Ovarian	0	0	0
15P6656825-1	Ovarian	2	0.02	0
15P6651892-1	Ovarian	0	0	0
15P6652359-1	Ovarian	4	0.2075	0.227239234
14P1004412-1	Ovarian	14	0.099357143	0.223643992
15P6653234-1	Ovarian	6	0.193166667	0.247161438
15P6653170-1	Ovarian	11	0.011818182	0
15P6652786-1	Ovarian	3	0.016	0
14P0973640	Ovarian	1	0.008	0
15P6656801-1	Ovarian	1	0.007	0
15P6653192-1	Ovarian	4	0.08775	0.053035986
15P6653240-1	Ovarian	2	0.005	0
15P6653220-1	Ovarian	1	0.005	0
15P6658589-1	Urinary	15	0.420133333	0.629339452
15P6652774-1	Urinary	10	0.0404	0.05919783
15P6653011-1	Brain	1	0.014	0
15S6651920-1	Prostate	6	0.034666667	0.086907028
15P6653252-1	Prostate	3	0.115666667	0.090258107
15P6651145-1	Prostate	5	0.223	0.253668689
15P6652775-1	Prostate	5	0.2786	0.615161866
15P6653178-1	Prostate	8	0.136625	0.212796787

15P6653248-1	Prostate	2	0.0065	0.033942454
15P6653222-1	Prostate	6	0.015666667	0.028462785
15P6656542-1	Sarcoma	2	0.2815	0.102729947
14P1113655	Sarcoma	0	0	0
15P6226230-1	Breast	0	0	0
15P6652157-1	Breast	5	0.0378	0.051497365
15P6651349-1	Breast	3	0.076333333	0.109239902
15P6653217-1	Breast	0	0	0
15P6653201-1	Breast	6	0.122833333	0.069904242
14P0973390	Breast	3	0.179666667	0.229327757
15P6653206-1	Breast	2	0.183	0.339381076
14P0951863	Breast	26	0.098884615	0.510480856
15P6220005-1	Breast	1	0.005	0
14P1005818-1	Breast	2	0.101	0.260254934
14P1005818-2	Breast	2	0.1915	0.475762298
15P6653193-1	Breast	6	0.024333333	0.030172081
15P6651130-1	Breast	0	0	0
15P0201525-1	Breast	0	0	0
14P1113686	Breast	3	0.013666667	0
15P6653218-1	Breast	4	0.2715	0.272666702
15P6658732-1	Kidney	0	0	0
15P6653189-1	Kidney	10	0.116	0.139971233
15P6651925-1	Kidney	0	0	0
15P6653185-1	Kidney	24	0.034541667	0.043863828
14P1007957-1	Esophagus	0	0	0
15P6658733-1	Esophagus	0	0	0
14P1010179	Esophagus	13	0.091692308	0.148532209
14P1112999	Esophagus	3	0.015666667	0.037563001
15P6652787-1	Odiduct	5	0.138	0.088576241
15P6653228-1	Head&Neck	0	0	0
15P6652981-1	Head&Neck	5	0.0334	0.036663166
15P6654180-1	Head&Neck	6	0.14	0.343960522
15P6653191-1	Head&Neck	3	0.086333333	0.13298039
14P1114363-1	Unknow	15	0.1008	0.170220157
14P1009600	Unknow	10	0.2589	0.221831563
14P1011058	Unknow	2	0.0095	0
14P1114098-1	Unknow	7	0.029142857	0
14P1114373-1	Unknow	1	0.017	0
15P6651951-1	Stomach	0	0	0
15P6652784-1	Stomach	52	0.144423077	0.294842894
15P6653261-1	Stomach	0	0	0
15P6653197-1	Stomach	0	0	0
15P6653205-1	Stomach	0	0	0
14P1012171	Stomach	0	0	0.04230244

14P1006996-1	Stomach	10	0.1993	0.378794082
15P6653172-1	Stomach	10	0.0269	0
14P1008017-1	Stomach	0	0	0
15P6653195-1	Stomach	8	0.0365	0.063398046
14P1007958-1	Stomach	0	0	0.042912187
15P1875721-1	GIST	0	0	0
15P6651691-1	Unknow	1	0.009	0.050555753
15P6653200-1	Fibrosarcoma	6	0.062166667	0.091158194
15P6653194-1	SIST	0	0	0
15P6653187-1	Thymic	6	0.275	0.26576364
14P1113517	Pancrease	1	0.006	0
15P6653979-1	Pancrease	2	0.1355	0.095874427
15P6652481-1	Pancrease	0	0	0
15P6658045-1	Pancrease	8	0.336625	0.322894514
15P6653247-1	Pancrease	13	0.011692308	0
14P1112533	Pancrease	0	0	0
14P1011866	Pancrease	2	0.0115	0
15P6653249-1	Pancrease	1	0.1	0.138650611
15P6226233-1	Pancrease	7	0.022428571	0.037242546
15P6653259-1	Pancrease	4	0.0405	0.028335921
15P6226237-1	Pancrease	5	0.1994	0.156404556
15P6650388-1	Pancrease	1	0.016	0
15P6653210-1	Endometrium	20	0.058	0
14P1112320	Trophoblastic	1	0.075	0